This company listing is no longer active
NUGX Stock Overview
NuGenerex Immuno-Oncology, Inc., an oncology company, focuses on the modulation of the immune system to treat cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
NuGenerex Immuno-Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.30 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 9,900.00% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| NUGX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 1.0% | 0.3% |
| 1Y | 9,900.0% | 19.1% | 22.5% |
Return vs Industry: NUGX exceeded the US Pharmaceuticals industry which returned -1.7% over the past year.
Return vs Market: NUGX exceeded the US Market which returned 4% over the past year.
Price Volatility
| NUGX volatility | |
|---|---|
| NUGX Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: NUGX's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine NUGX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | n/a | Joe Moscato | www.generex.com/nugenerex-family-of-companies |
NuGenerex Immuno-Oncology, Inc., an oncology company, focuses on the modulation of the immune system to treat cancer. The company is developing immunotherapeutic products and vaccines. It is developing AE37, a peptide immunotherapeutic vaccine, which is in Phase II clinical trials for the treatment of metastatic triple negative breast cancer.
NuGenerex Immuno-Oncology, Inc. Fundamentals Summary
| NUGX fundamental statistics | |
|---|---|
| Market cap | US$10.12k |
| Earnings (TTM) | -US$6.29m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs NUGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NUGX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$6.29m |
| Earnings | -US$6.29m |
Last Reported Earnings
Apr 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did NUGX perform over the long term?
See historical performance and comparison